Break-out Time
There are four reasons why this stock is poised to break out. One of the catalysts should drive volume and the stock price big-time.
A Waste Management Services Star
Scorpex, Inc. is positioned to become the dominant provider of integrated waste management services in a regional market in Mexico that represents billions in annual revenue. The Company has already received an offer to provide waste disposal services of up to 800 tons worth of waste per day. This contract alone is worth hundreds of millions in revenue annually.

With no direct competition, Scorpex should generate substantial revenue and profitability. Current methods of waste disposal are ineffective and costly with landfills overflowing. In fact, the primary means of waste disposal is transportation to the U.S. and abroad.
Must-Own Stock for Holiday Season
Omni Ventures is leveraging the success and popularity of its flagship subsidiary, PRVCY Couture, Inc., to emerge as a leader in the premium consumer brand segment. Since its re-launch, PRVCY Couture, Inc. remains a premium designer jeans of choice among “A” list celebrities, which we expect will prompt a sustained surge in sales. Celebrities include Kim Kardashian, Jessica Alba, Mark Wahlberg, Ashton Kutcher, Miley Cyrus, Eva Longoria, and many others.
MIMV: Stock Can Triple from Here
We came across some great news related to Mimvi. After further review we believe that the stock can triple from here after the recent decline on very light volume.
Get Ready for the Power Play
Today we are introducing what is clearly the world’s next major renewable energy player: ecoTECH Energy Group, Inc. (OTCBB: ECTH). The Company is positioned to generate nearly $200M in revenue in the next two years with huge operating profitability. Bottom line: ECTH could rise by nearly five-fold over the next six months.
New Approach to Regenerative Medicine
Leveraging its proprietary non-invasive technology, SANUWAVE is well positioned to garner a share of multiple regenerative medicine market segments totaling $10 billion.
The Company has already completed a pivotal Phase III Investigational Device Exemption (IDE) clinical trial for the treatment of diabetic foot ulcers for its dermaPACE® device. The trial was very favorable, demonstrating statistically and clinically significant results. The dermaPACE® device to treat diabetic foot ulcers could be approved sometime in 1H12
SG Better Than Advertised; Next Stop $0.50.
Nuvilex has been transformed from a cult-stock with a quirky history to an emerging, broad-based, multi-functional, therapeutic enhancement platform. Think back to the BASF commercials from the late 1990’s. “We don’t make….we make everything better.” In essence, that is what Nuvilex has with the live-cell encapsulation technology/delivery platform being acquired as part of the SG Austria transaction.
From Zero to Sixty
Earlier this morning, SunSi Energies, Inc. announced solid fiscal 4Q11 and FY11 financial results that included the Company’s first-ever quarterly profit.
One More Piece to the Puzzle
Early this morning, OHR announced that it was awarded a patent that includes claims related to composition of matter for the lactate salt form of Squalamine and its delivery using any pharmaceutically acceptable carrier.
Raising Estimates on Fast Growing Stock

It should be a rough ride. But here is a company that is growing revenues at an amazing clip, prompting an increase in our forecast READMORE

<< Start < Prev 41 42 43 44 45 Next > End >>

Page 44 of 45